Keros Therapeutics Inc (KROS) - News Archive

The realm of therapeutic innovations is consistently evolving, driven by breakthrough clinical trials and economic performance. Keros Therapeutics, a front-runner in biopharmaceutical advancements, has recently announce...

Keros Therapeutics, Inc. (NASDAQ: KROS) has come under the investigative spotlight of Bragar Eagel & Squire, P.C. a law firm renowned for its representation of stockholder rights. On January 24, 2025, the firm announced...

Keros Therapeutics, Inc. a biopharmaceutical firm dedicated to developing therapeutics targeting disorders arising from dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins, recently...

In a significant advancement for the treatment of hematological disorders, Keros Therapeutics, Inc. a clinical-stage biopharmaceutical company, presented pivotal findings from its ongoing Phase 2 clinical trials of elri...

In recent months, Keros Therapeutics, Inc. has made significant strides in its clinical research endeavors, focusing on the modulation of the transforming growth factor-beta (TGF-β) signaling pathway. This pathway has b...

Advancing Treatments for Hematologic Disorders: Keros Therapeutics Pioneering Work on Elritercept (KER-050) Keros Therapeutics, Inc. (Nasdaq: KROS) has continuously made strides in developing innovative therapeutics tar...

Keros Therapeutics, a clinical-stage biopharmaceutical company specializing in therapeutics targeting dysfunctional signaling of the transforming growth factor-beta (TGF-) family of proteins, has recently announced sign...

Keros Therapeutics, a clinical-stage biopharmaceutical company specializing in therapies targeting dysfunctional signaling of the transforming growth factor-beta (TGF-) protein family, has recently announced the pricing...

Keros Therapeutics Aims to Harness Transformative Potential of TGF-Beta Proteins with New Public OfferingLEXINGTON, Mass., Jan. 03, 2024 - Keros Therapeutics, a pioneering clinical-stage biopharmaceutical company dedica...

Keros Therapeutics to Charter a New Course in Obesity Treatment with KER-065LEXINGTON, Mass., Jan. 03, 2024 - In a significant announcement that is set to bring new hope for obesity treatments worldwide, Keros Therapeut...